Introduction: Study 303 (SUNRISE-2; NCT02952820) evaluated lemborexant (LEM) efficacy in subjects with insomnia. This post-hoc analysis examined sleep outcomes in the subgroup of subjects...
INTRODUCTION: The insomnia severity index (ISI) is a self-report instrument that evaluates perception of insomnia severity. In Study 303 (SUNRISE-2), lemborexant (LEM) showed greater red...
Introduction: Lemborexant is approved in the US for treating insomnia in adults. We evaluated the evidence-base for lemborexant and suvorexant, both dual orexin receptor antagonists (DORA...
Introduction: The Fatigue Severity Scale (FSS) assesses impact of fatigue on patients’ lives. Lemborexant (LEM) efficacy was examined in the subgroup of subjects with baseline FSS total s...
Background
Pancreatic adenocarcinoma (PDAC) is one of the most aggressive cancer histologies, as evidenced by high recurrence rate (85%) and poor 5-year overall survival...